1. Almost 50 non-oncology drugs found to kill cancer cells —Chi-Med stops pancreatic cancer trial upon early success — GSK gets speedy review for one of its top drug prospects— See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

52-week low; not a good sign

Discussion in 'Celgene' started by anonymous, May 22, 2018 at 11:46 AM.

  1. anonymous

    anonymous Guest

    Don't forget that external factors can influence the stock price. Amgen presented (early!) data that week for AMG 420, an ADC targeting BCMA, that resulted in prolonged remissions in MM patients. This represents a possible threat to bb2121, although it is too early to tell where the comparative advantages lie.
     

  2. anonymous

    anonymous Guest

    And now another discontinued trial and concept further decline the stock. This company better get its act together. The BOD needs to reevaluate sooner than later.